Meeting
2018 ASCO Annual Meeting
Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.
Authors
Jennifer N. Brudno
Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD
Jennifer N. Brudno , Steven D. Hartman , Stefania Pittaluga , David Stroncek , Norris Lam , Jennifer Ann Kanakry , Steven Zivko Pavletic , Lekha Mikkilineni , Mohammadhadi Bagheri , Mark J. Roschewski , Robert M. Dean , Jeremy J. Rose , Rashmika Patel , Brenna G. Hansen , Ronald Gress , James Kochenderfer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT02659943
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3052)
DOI
10.1200/JCO.2018.36.15_suppl.3052
Abstract #
3052
Poster Bd #
266
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.
First Author: Navin R. Pinto
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2022 ASCO Annual Meeting
Decreasing HPK1 expression in CD19 CAR-T cells: A novel strategy to overcome challenges of cell therapy for adult (r/r) B-ALL.
First Author: Na Zhang